切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2024, Vol. 18 ›› Issue (04) : 305 -308. doi: 10.3877/cma.j.issn.1674-0793.2024.04.014

综述

中晚期肝细胞癌介入治疗的进展及前景
汤宏涛1, 何坤1,†()   
  1. 1. 528400　广东医科大学附属中山市人民医院肝胆外科
  • 收稿日期:2023-11-17 出版日期:2024-08-01
  • 通信作者: 何坤
  • 基金资助:
    广东省科技攻关计划(2017B1044)

Progress and prospects of interventional therapy for advanced hepatocellular carcinoma

Hongtao Tang1, Kun He1,†()   

  1. 1. Department of Hepatobiliary Surgery, Zhongshan City People’s Hospital Affiliated to Guangdong Medical University, Zhongshan 528400, China
  • Received:2023-11-17 Published:2024-08-01
  • Corresponding author: Kun He
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

汤宏涛, 何坤. 中晚期肝细胞癌介入治疗的进展及前景[J]. 中华普通外科学文献(电子版), 2024, 18(04): 305-308.

Hongtao Tang, Kun He. Progress and prospects of interventional therapy for advanced hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(04): 305-308.

肝细胞癌（HCC）是国内常见恶性肿瘤之一，严重威胁人民身体健康。外科手术切除病灶是HCC患者获得长期生存的主要手段之一，但有部分患者在初诊时已处于中晚期而不可行手术治疗。近年来介入治疗不断发展，在HCC领域取得诸多优异成绩，合理应用可有效延长患者生存时间。本文就血管介入治疗在中晚期HCC治疗领域中的临床应用研究进展和前景进行论述。

关键词: 癌，肝细胞, 经导管动脉化疗栓塞, 经肝动脉灌注化疗, 免疫检查点抑制剂, 抗血管生成靶向药物, 联合治疗

Hepatocellular carcinoma (HCC) is one of the common malignant tumors in China, which seriously threatens the health. Surgical resection of HCC lesions is one of the main means to achieve long-term survival, but some patients are already at the middle or late stage since the time of initial diagnosis and surgical resection is not feasible. In recent years, interventional therapy has continuously developed and achieved excellent achievements in the field of HCC, and reasonable application can effectively prolong the survival time of patients. This article discusses the clinical research progress and prospects of vascular interventional therapy in the treatment of advanced HCC.

Key words: Carcinoma, hepatocellular, Transcatheter arterial chemoembolization, Hepatic artery infusionchemotherapy, Immune checkpoint inhibitors, Antiangiogenic targeted drugs, Combination therapy
[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
[3]
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识（2021版） [J]. 中华消化外科杂志, 2021, 20(6): 600-616.
[4]
Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675.
[5]
Lai Z, He M, Bu X, et al. Lenvatinib, Toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase Ⅱ trial[J]. Eur J Cancer, 2022, 174: 68-77.
[6]
He M, Ming S, Lai Z, Li Q. A phase Ⅱ trial of Lenvatinib plus Toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study)[J]. J Clin Oncol, 2021, 39 (suppl 15): 4083.
[7]
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83.
[8]
Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(2): 150-160.
[9]
Hu Z, Yang Z, Wang J, et al. Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus[J]. Front Pharmacol, 2023, 14: 1223632.
[10]
Finn RS, Ryoo BY, Hsu CH, et al. Results from the MORPHEUS-liver study: phase Ⅰb/Ⅱ randomized evaluation of Tiragolumab (tira) in combination with Atezolizumab (atezo) and Bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2023, suppl 16: abstr 4010.
[11]
Dawson L, Winter K, Knox J, et al. NRG/RTOG 1112: randomized phase Ⅲ study of Sorafenib vs. Stereotactic body radiation therapy (SBRT) followed by Sorafenib in hepatocellular carcinoma (HCC) (NCT01730937)[J]. Int J Radiat Oncol Biol Phys, 2022, 114(5): 1057.
[12]
Qin SK. First-line Lenvatinib plus Pembrolizumab for advanced heptocellular carcinoma: LEAP-002 Asian subgroup analysis[G]. JSMO, 2023.
[13]
Sun T, Ren Y, Sun B, et al. The feasibility of TACE combined with TKIs plus PD-1 antibody for advanced HCC[J]. J Hepatocell Carcinoma, 2023, 10: 447-457.
[14]
Yu B, Zhang N, Feng Y, et al. Tyrosine kinase inhibitors plus Anti-PD-1 antibodies with hepatic arterial infusion chemotherapy or transarterial chemoembolization for unresectable hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2023, 10: 1735-1748.
[15]
Brozzetti S, D’Alterio C, Bini S, et al. Surgical resection is superior to TACE in the treatment of HCC in a well selected cohort of BCLC-B elderly patients-a retrospective observational study[J]. Cancers (Basel), 2022, 14(18): 4422.
[16]
Liu J, Yan S, Zhang G, et al. A retrospective study of transarterial chemoembolization (TACE) combined with Lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma[J]. Oncol Lett, 2023, 26(6): 507.
[17]
Lin LW, Ke K, Yan LY, et al. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization[J]. Front Oncol, 2023, 13: 1178428.
[18]
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[19]
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a Bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[20]
Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠ b study of Lenvatinib plus Pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[1] 丁丁, 杨云川, 马翔, 马中正, 霍俊一, 周磊. 术前C-反应蛋白-白蛋白-淋巴细胞比值在肝细胞癌预后中的价值评估[J]. 中华普通外科学文献(电子版), 2024, 18(04): 261-265.
[2] 陈怡芳, 黄晓卉. 肝细胞癌中对氧磷酶2的表达及临床意义[J]. 中华普通外科学文献(电子版), 2024, 18(03): 186-191.
[3] 陆朝阳, 金也, 孙备. 腹腔镜解剖性肝切除的发展[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 363-366.
[4] 龚财芳, 赵俊宇, 游川. 围手术期肠内营养在肝癌肝切除患者中有效性及安全性的Meta分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 551-556.
[5] 张杰, 田广磊, 陈雄. 基于生物信息学分析探讨肝癌BRD4与预后关系及其ceRNA调控网络构建[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 568-576.
[6] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 407-449.
[7] 钟造茂, 罗文超, 蔡满航, 陈显育, 钟跃思. 肝癌肝切除术后肝衰竭的危险因素分析及列线图模型构建[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 289-295.
[8] 曾谣, 谢琴, 陈显育, 王平根, 毛玲秋, 何丹玲, 杜飞, 郑希彦, 何函樨. CDC42EP2基因与肝癌预后、免疫细胞浸润关系及其对细胞迁移侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 363-369.
[9] 杨兴业, 彭旭云, 曾倩, 梁伟铖, 肖翠翠, 郑俊, 姚嘉. LMO7通过靶向铁死亡促进肝细胞癌生长[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 370-376.
[10] 仝心语, 谭凯, 白亮亮, 杜锡林. 外泌体在肝细胞癌诊疗中的应用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 384-388.
[11] 陈显育, 曾谣, 莫钊鸿, 翟航, 张广权, 钟造茂, 陈署贤. 生物信息学分析CETP基因在肝癌中表达及其对预后和免疫的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 214-219.
[12] 吕垒, 冯啸, 何凯明, 高成立, 杨洲, 贾昌昌, 傅斌生. 组蛋白伴侣VPS72驱动H2AFZ的表达并协同促进肝癌进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 220-226.
[13] 宋燕京, 乔江春, 宋京海. 中晚期肝癌TACE联合免疫靶向转化治疗后右半肝切除术一例[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 227-230.
[14] 张朋伟, 杨朝凤, 李杨. 结直肠癌肝转移介入治疗的研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(02): 177-182.
[15] 楚海强, 杨远游, 任刚. 胰腺癌放射治疗联合其他治疗方法的研究进展[J]. 中华临床医师杂志(电子版), 2024, 18(04): 392-396.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号